Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Glandular and Epithelial » Carcinoma » Adenocarcinoma
Description
A malignant epithelial tumor with a glandular organization. MeSH
Hierarchy View
Subtype Terms (29)
Adenocarcinoma, Clear Cell
21 drugs (15 approved, 6 experimental)
Adenocarcinoma, Follicular
1 approved drug
Adenocarcinoma in Situ
2 approved drugs
Adenocarcinoma, Mucinous
10 approved drugs
Adenocarcinoma of Lung
73 drugs (38 approved, 35 experimental)
Adenocarcinoma, Papillary
3 drugs (2 approved, 1 experimental)
Adenocarcinoma, Scirrhous
1 experimental drug
Adrenocortical Carcinoma
48 drugs (30 approved, 18 experimental)
Carcinoid Tumor
43 drugs (30 approved, 13 experimental)
Carcinoma, Acinar Cell
4 drugs (3 approved, 1 experimental)
Carcinoma, Adenoid Cystic
58 drugs (37 approved, 21 experimental)
Carcinoma, Ductal
9 drugs (7 approved, 2 experimental)
Carcinoma, Endometrioid
15 drugs (9 approved, 6 experimental)
Carcinoma, Hepatocellular
559 drugs (183 approved, 376 experimental)
Carcinoma, Intraductal, Noninfiltrating
29 drugs (23 approved, 6 experimental)
Carcinoma, Islet Cell
28 drugs (22 approved, 6 experimental)
Carcinoma, Lobular
3 approved drugs
Carcinoma, Mucoepidermoid
37 drugs (26 approved, 11 experimental)
Carcinoma, Neuroendocrine
47 drugs (32 approved, 15 experimental)
Carcinoma, Renal Cell
484 drugs (163 approved, 321 experimental)
Carcinoma, Signet Ring Cell
2 approved drugs
Cholangiocarcinoma
196 drugs (94 approved, 102 experimental)
Choriocarcinoma
29 drugs (25 approved, 4 experimental)
Paget Disease, Extramammary
12 drugs (11 approved, 1 experimental)
Approved Indicated Drugs (1)
Phase 3 Indicated Drugs (24)
Phase 1 Indicated Drugs (36)
Other Experimental Indicated Drugs (4)
Organization Involved with Phase 4 Indications (31)
Organization Involved with Phase 3 Indications (200)
Academic and Community Cancer Research United
Academic Oncology Gastrointestinal Cancer Consortium
Arbeitsgemeinschaft fur Internistische Onkologie (AIO)
ARTIC group (oncologists and urologists association)
Assistance Publique - Hôpitaux de Paris
Badalona Hospital Germans Trias i Pujol
Belgian Group of Digestive Oncology
BioNumerik Pharmaceuticals, Inc.
Blokhin's Russian Cancer Research Center
Cancer and Leukemia Group B (CALGB)
Centre Catherine de Sienne - Nantes
Centre des Hautes Energie, Toulouse
Centre hospitalier de Mulhouse
Centre Hospitalier de Saint-Brieuc
Eastern Cooperative Oncology Group
ECOG-ACRIN Cancer Research Group
Egyptian Foundation for Cancer Research
European Organisation for Research and Treatment of Cancer
Federation Francophone de Cancerologie Digestive
Greater Washington Community Foundation
Groupe Francais De Pneumo-Cancerologie
Groupe Hospitalier Paris Saint Joseph
Grupo de Investigación Clínica en Oncología Radioterapia
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Gruppo Oncologico Chirurgico Cooperativo Italiano
Gruppo Oncologico del Nord-Ovest
Gruppo Oncologico Italiano di Ricerca Clinica
Hospital general Universitario de Ciudad Real
Hospital Universitario Lucus Augusti
Huazhong University of Science and Technology
IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest
Innovent Biologics (Suzhou) Co. Ltd.
Institut de Cancérologie de Lorraine
Institut de Cancerologie de l'Ouest Paul Papin
Italian Trial in Medical Oncology
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
L'Institut Mutualiste Montsouris-Paris
Moorgreen Hospital, Southampton
National Center for Complementary and Integrative Health (NCCIH)
National Cheng Kung University
North Central Cancer Treatment Group
OncoQuest Pharmaceuticals Inc.
Pancreatic Cancer Action Network
Pharmaceutical Research Associates, Inc. (PRA)
Radiation Therapy Oncology Group
Royal Marsden Hospital NHS Trust
Shanghai University of Traditional Chinese Medicine
Swiss Group for Clinical Cancer Research
The European Society for Hyperthermic Oncology
Universidad Autonoma de Barcelona
Universidad Autonoma de Madrid
Universidad Complutense de Madrid
University of California, Los Angeles
University of California, San Francisco
University of Nice Sophia Antipolis
University of Southern California
University of Texas at Houston
Organization Involved with Phase 2 Indications (435)
American Association for Cancer Research
Arbeitsgemeinschaft medikamentoese Tumortherapie
Asociación de Oncología Médica del Hospital de Cruces
Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials
Bankhead-Coley Florida Biomedical Research Program
Big Ten Cancer Research Consortium
Biocompatibles International plc
Blood Transfusion Centre of Slovenia
British Columbia Cancer Agency
Cancer Treatment Centers of America
Case Western Reserve University
Centre for Probe Development and Commercialization
Centre Georges Francois Leclerc
Centre Hospitalier La Source, Orleans
Chao Family Comprehensive Cancer Center
Chengdu Kanghong Biotech Co.,Ltd.
City of Hope National Medical Center
CNAO National Center of Oncological Hadrontherapy
E-Group ICT Software Informatikai Zrt.
First People's Hospital of Shangqiu
Fondazione del Piemonte per l'Oncologia
Foundation IRCCS San Matteo Hospital
GCP-Service International Ltd. & Co. KG
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Grupo Espanol Multidisciplinario del Cancer Digestivo
Grupo Gallego de Investigaciones Oncologicas
Guangdong Province Association Study of Thoracic Oncology
Hamilton Health Sciences Corporation
Hellenic Cooperative Oncology Group
Herbert Irving Comprehensive Cancer Center
HonorHealth Research Institute
Hoosier Cancer Research Network
Hospital Universitario Carlos Haya
Hospital Universitario de Fuenlabrada
Hospital Universitario Santander
Icahn School of Medicine at Mount Sinai
Institute for Developmental Cancer Therapeutics
Institut Mutualiste Montsouris
Intergroupe Francophone de Cancerologie Thoracique
International Group of Endovascular Oncology
James and Esther King Biomedical Research Program
King Faisal Specialist Hospital
Kliniken Nordoberpfalz AG Klinikum Weiden Medizinische Kliniken I
Korean Association for the Study of Targeted Therapy
Laboratorio Elea S.A.C.I.F. y A.
Lousiana Health Sciences Center - Shreveport
Maryland Cigarette Restitution Fund
Memorial Cancer Institute, Florida
National Comprehensive Cancer Network
Nationales Centrum fur Tumorerkrankungen
National Institutes of Health (NIH)
National Natural Science Foundation of China
National University of Singapore
New Mexico Cancer Care Alliance
North Eastern Germany Society of Gynaecologic Oncology
Northeast Ohio Medical University
Norwegian University of Science and Technology
Oddzial Kliniczny Kliniki Onkologii
Oddzial Onkologii Klinicznej im L Rydygiera
Ontario Institute for Cancer Research
Oregon Health and Science University
Pancreatic Cancer Research Team
Philipps University of Marburg
Phoenix Clinical Research Center
Puyang Oil Field General Hospital
Queensland University of Technology
Radiation Oncology Center of Olathe
Regionalny Szpital Specjalistyczny Latawiec
Salk Institute for Biological Studies
Samyang Biopharmaceuticals Corporation
Shanghai Junshi Bioscience Co.,Ltd.
Shenma Medical Group General Hospital
Simcere Pharmaceutical Co., Ltd
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
State University of New York, Buffalo
St. Luke's-Roosevelt Hospital Center
Suzhou Sheng Diya Biomedical Co., Ltd.
Taichung Veterans General Hospital
Technical University of Munich
The First People's Hospital of Changzhou
The University of Texas, Dallas
The Wayne D. Kuni and Joan E. Kuni Foundation
Translational Oncology Research International
University Hospital Hradec Kralove
University of Alabama, Birmingham
University of California, Davis
University of California, Irvine
University of California, San Diego
University of Colorado, Denver
University of Medicine and Dentistry of New Jersey
University of North Carolina at Chapel Hill
University of Texas, Galveston
University of Texas, San Antonio
Virginia Commonwealth University
Virginia Polytechnic Institute and State University
Organization Involved with Phase 1 Indications (93)
American Society for Gastrointestinal Endoscopy
Bio-Cancer Treatment International Limited
BioMed Valley Discoveries, Inc
Blueprint Medicines Corporation
Dynavax Technologies Corporation
Eastern Regional Medical Center
Infinity Pharmaceuticals, Inc.
Institut National de la Santé Et de la Recherche Médicale, France
Methodist Cancer Center, Houston, Texas
Molecular Insight Pharmaceuticals
National Institute for Health Research, United Kingdom
Prostate Cancer Clinical Trials Consortium
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Organization Involved with Other Experimental Indications (15)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.